Cardinal Health Reiterates Specialty/MSO Growth at Conference, but Valuation Remains Stretched

What happened

Cardinal Health presented at the 2026 Global Healthcare Conference, providing an update on its specialty and MSO-driven growth strategy. The presentation likely reinforced the company's recent guidance of at least $10 non-GAAP EPS for fiscal 2026 and specialty revenue exceeding $50 billion, focusing on the expansion of The Specialty Alliance and at-home solutions. However, the market's reaction to the conference was likely muted, as shares have already priced in significant optimism following multiple guidance raises and a 65% run over the past year. The core risk remains that the stock trades at around 22x forward non-GAAP earnings with negative tangible book value, leaving little cushion if any of the company's key assumptions—such as MSO integration, customer retention, or favorable drug pricing policy—fail to materialize. Management's presentation likely did not address the growing gap between GAAP and non-GAAP earnings, which is driven by heavy acquisition-related amortization and rising interest expense, nor did it provide a clear framework for fiscal 2027 EPS growth.

Implication

The conference presentation is unlikely to change the fundamental investment thesis, which is that Cardinal Health is a high-quality operator but its stock has become over-owned and overvalued due to momentum and non-GAAP-adjusted earnings growth. The company's reliance on acquisitions to drive EPS growth, combined with rising leverage and interest costs, means that true GAAP earnings power may be lower than reported non-GAAP figures suggest. With CVS Health accounting for approximately 30% of revenue and IRA-related drug pricing reforms looming, there is asymmetric downside risk if any of these key relationships or regulatory frameworks deteriorate. Management's reiterated guidance for fiscal 2026 may be achievable, but the lack of visibility on fiscal 2027 and the potential for multiple compression from peak valuation levels argue against adding new positions at this time. Accordingly, investors should treat any near-term strength as an opportunity to reduce exposure, and only consider re-engaging if the stock pulls back to a level that offers a more reasonable margin of safety, such as below $185.

Thesis delta

No shift from the DeepValue master report. The conference presentation appears to be a routine update that neither strengthens nor weakens the core argument that CAH is currently overvalued. The potential sell stance remains intact.